Published in Vaccine Weekly, January 16th, 2002
"Safe and potent new adjuvants are needed for vaccines that are administered to mucosal surfaces," according to Curtis P. Bradney and colleagues at Duke University Medical Center's Departments of Medicine, Human Vaccine Institute, and Center for AIDS Research in Durham, North Carolina.
Several interleukins in combination significantly enhanced the efficacy of a vaccine candidate, to a higher degree than other potential adjuvants, Bradney and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly